TY - JOUR
T1 - The donor's dilemma
AU - Holtan, Shernan G.
AU - Weisdorf, Daniel J.
PY - 2014/6/5
Y1 - 2014/6/5
N2 - In this issue of Blood, Pulsipher et al identify key differences in adverse events related to donation for hematopoietic cell transplantation (HCT) from a prospective cohort of nearly 9500 unrelated allogeneic donors recruited through the National Marrow Donor Program.1 Although the rates of life-threatening complications were very low overall (<0.3%) for donors of both peripheral blood and bone marrow, those donating bone marrow had a 4-fold increased risk of experiencing a serious adverse event. Most adverse events were acute in nature, resolving within a matter of days to weeks, and importantly, no deaths as a result of donation procedures occurred. This prospective study, with more than 20 000 donor-years of follow-up after granulocyte colony-stimulating factor administration, also showed no increased risk for hematologic or other cancers, autoimmune diseases, or thrombosis associated with growth factor mobilization. In fact, donors in this cohort had a significantly lower incidence of cancer compared with the general population, regardless of granulocyte colonystimulating factor exposure.
AB - In this issue of Blood, Pulsipher et al identify key differences in adverse events related to donation for hematopoietic cell transplantation (HCT) from a prospective cohort of nearly 9500 unrelated allogeneic donors recruited through the National Marrow Donor Program.1 Although the rates of life-threatening complications were very low overall (<0.3%) for donors of both peripheral blood and bone marrow, those donating bone marrow had a 4-fold increased risk of experiencing a serious adverse event. Most adverse events were acute in nature, resolving within a matter of days to weeks, and importantly, no deaths as a result of donation procedures occurred. This prospective study, with more than 20 000 donor-years of follow-up after granulocyte colony-stimulating factor administration, also showed no increased risk for hematologic or other cancers, autoimmune diseases, or thrombosis associated with growth factor mobilization. In fact, donors in this cohort had a significantly lower incidence of cancer compared with the general population, regardless of granulocyte colonystimulating factor exposure.
UR - http://www.scopus.com/inward/record.url?scp=84902215523&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902215523&partnerID=8YFLogxK
U2 - 10.1182/blood-2014-04-571661
DO - 10.1182/blood-2014-04-571661
M3 - Review article
C2 - 24904102
AN - SCOPUS:84902215523
SN - 0006-4971
VL - 123
SP - 3538
EP - 3539
JO - Blood
JF - Blood
IS - 23
ER -